ARCHIVE

The advent of new therapeutic classes and the updating of international recommendations have justified the development of recent recommendations by the Moroccan Society of Rheumatology. Methods: Guidelines were drafted by a core steering committee after performing a literature search. A multidisciplinary task force, including three fellows, eleven rheumatologists, a specialist in physical medicine and rehabilitation, an epidemiologist from hospital-university, hospital, and liberal sectors and one patient assessed the Best Practice Guidelines using 2 rounds of anonymous online voting by modified Delphi process. Thus, 19 recommendations were developed. Recommendation 1 concerns the therapeutic principles, Recommendation 2 insists on the information and education of the patient, Recommendation 3 concerns the general measures to be adopted, namely physical activity, smoking cessation and psychological support, Recommendation 4 concerns Non-Steroidal Anti-Inflammatory Drugs which constitute the first-line treatment, Recommendations 5 to 7 concern the use of analgesics, of general and local corticosteroid therapy and conventional synthetic disease-modifying antirheumatic drugs, Recommendations 8 to 13 deal with the use of biologic agents, including new classes and their indications in radiographic and non-radiographic axial and peripheral spondyloarthritis, follow-up and management in case of failure or remission, Recommendation 14 deals with the indication for Janus kinase inhibitors drugs, Recommendation 15 deals with physical treatment, and Recommendation 16 deals with the indication of surgery. Recommendations 17-19 deal with special situations, namely fibromyalgia, vaccination, and pregnancy. A well-defined therapeutic strategy with first- and second-line treatments has been established.

Cite this article as: Jaouad N, Oulkadi L, Bentaleb I, Bezza A, El Maghraoui A, Niamane R, El Bouchti I, Larhrissi S, Ichchou L, Janani S, Abourazzak FE, Akasbi N, Erraoui M, Karkouri S, Hmamouchi I, Bahiri R. Recommendations of the Moroccan Society of Rheumatology (SMR) for the Therapeutic Management of Spondyloarthritis (SpA) including Psoriatic Arthritis (PsA). Mediterr J Rheumatol 2023;34(2):139-51.

Article Submitted: 17 Oct 2022; Revised Form: 01 Jun 2023; Article Accepted: 04 Jun 2023; Available Online: 30 Jun 2023

https://doi.org/10.31138/mjr.34.2.139

This work is licensed under a Creative Commons Attribution 4.0 International License.

©2023 The Author(s).